Nutrition Department, La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Autonomous University of Madrid, Madrid, Spain.
Otolaryngology Department, La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Autonomous University of Madrid, Madrid, Spain.
JPEN J Parenter Enteral Nutr. 2018 Feb;42(2):371-379. doi: 10.1177/0148607116676839. Epub 2017 Dec 12.
The perioperative use of immunomodulatory nutrition formulas in patients with head and neck cancer reduces the number of postoperative infections and the length of hospital stay.
An exploratory, randomized, controlled, blind, clinical trial was designed to examine the effect of the preoperative consumption of a new, immunomodulatory, oral nutrition formula in patients with head and neck cancer.
Thirty-eight patients were randomized to receive either 400 mL/d of either the new immunomodulatory formula (IF) or that commonly used in clinical practice (CF) over 10 days prior to surgery. Thirty-three patients completed the study. Compliance, tolerance, the length of hospital stay, the incidence of infections and noninfectious complications before discharge, and the same up to 15 and 30 days after discharge were recorded.
The percentage of patients who developed infections before discharge was significantly lower in the IF than in the CF group (P = .013), as was the number of infections/100 patients/d (P = .035). The length of hospital stay was significantly shorter in the IF group (P = .001). Both formulas were safe and well tolerated. No other differences were detected. These results suggest preoperative consumption of the new formula to be beneficial for patients with neck and head cancer. Further trials are needed to confirm these results and to test the efficacy of the formula in patients with other conditions.
The new formula can be safely prescribed as part of the preoperative treatment of patients with head and neck cancer and might reduce the problem of postoperative infection.
头颈部癌症患者围手术期使用免疫调节型营养配方可减少术后感染的发生次数和住院时间。
设计了一项探索性、随机、对照、盲法临床试验，以检验术前使用新型免疫调节型口服营养配方对头颈部癌症患者的影响。
38 例患者随机分为两组，分别在术前 10 天内每天接受 400 mL 新免疫调节配方（IF）或临床常用配方（CF）。33 例患者完成了研究。记录了依从性、耐受性、住院时间、出院前感染和非感染性并发症的发生率，以及出院后 15 天和 30 天的相同情况。
IF 组出院前发生感染的患者比例明显低于 CF 组（P =.013），每 100 例患者/天的感染人数也明显低于 CF 组（P =.035）。IF 组的住院时间明显缩短（P =.001）。两种配方均安全且耐受性良好。未发现其他差异。这些结果表明，术前使用新配方对头颈癌患者有益。需要进一步的试验来证实这些结果，并检验该配方在其他疾病患者中的疗效。
新型配方可安全地用于头颈部癌症患者的术前治疗，可能减少术后感染问题。
